Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Account Payables (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Change in Account Payables for 9 consecutive years, with -$3.8 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Account Payables rose 23.53% year-over-year to -$3.8 million; the TTM value through Mar 2026 reached -$5.7 million, down 242.29%, while the annual FY2025 figure was -$6.9 million, 322.0% down from the prior year.
  • Change in Account Payables hit -$3.8 million in Q1 2026 for Bicycle Therapeutics, down from -$2.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $10.7 million in Q4 2024 and bottomed at -$5.9 million in Q1 2024.
  • Average Change in Account Payables over 5 years is $173470.6, with a median of -$431000.0 recorded in 2024.
  • Year-over-year, Change in Account Payables crashed 684.71% in 2023 and then skyrocketed 1515.08% in 2025.
  • Bicycle Therapeutics' Change in Account Payables stood at -$2.4 million in 2022, then soared by 275.82% to $4.2 million in 2023, then skyrocketed by 156.49% to $10.7 million in 2024, then crashed by 126.96% to -$2.9 million in 2025, then tumbled by 33.22% to -$3.8 million in 2026.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$3.8 million, -$2.9 million, and -$5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.